Study of XmAb412 in Healthy Participants

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Not Applicable - Healthy Adult Participants

In brief

This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants

Key facts

Study ID

NCT07713485

Run by

Xencor, Inc.

People needed

128

Starts

2026-07-13

Expected to finish

2028-03-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-55 years old
• Must be in good health with no significant medical history
• BMI 18-35 kg/m2
• Contraceptive use consistent with local regulations
• Able and willing to provide written informed consent

You may not qualify if…

• Any physical condition that prohibits study completion
• Known hypersensitivity to the trial intervention or any of its components
• HIV, hepatitis B and hepatitis C positive
• Clinically significant abnormal ECG
• Use of other investigational products within 5 half lives from Screening
• Blood or plasma donation within 60 days from Screening
• Pregnant or breastfeeding
• Other protocol defined inclusion/exclusion criteria apply

Where it is running

• Xencor Investigative Site — Joondalup, Western Australia, Australia (enrolling)
• Xencor Investigative Site — Nedlands, Western Australia, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.